Standard peritoneal glucose solutions may induce the formation of advanced glycation end products (AGEs). Preliminary data suggest that AGE formation may be less with the use of polyglucose solutions (icodextrin). Therefore, we investigated whether the use of icodextrin for the long dwell would result in a reduction in plasma and dialysate levels of the AGE products N∊-(carboxymethyl) lysine (CML) and N∊-(carboxyethyl)lysine (CEL).
Patients and Methods
40 patients were randomized to treatment with standard glucose solutions (1.36%) and icodextrin for the long dwell during a 4-month study period; 32 patients completed the study. CML was assessed by stable isotope dilution/tandem mass spectrometry.
Results
CML levels in plasma increased significantly in patients treated with icodextrin (0.146 ± 0.056 at start vs 0.188 ± 0.069 μmol/mmol Lys at the end of the study, p < 0.0001) but did not change in the control group (0.183 ± 0.090 vs 0.188 ± 0.085 μmol/mmol Lys). The same held true for CML levels in dialysate (0.28 ± 0.09 at start vs 0.33 ± 0.11 μmol/mmol Lys at the end of the study, p < 0.025). No change was observed in patients treated with the control solutions (0.31 ± 0.11 at start vs 0.31 ± 0.07 μmol/mmol Lys).
Conclusion
Contrary to the hypothesis, plasma and dialysate levels of CML increased in patients treated using icodextrin for the long dwell.
RajD.S., ChoudhuryD., WelbourneT.C., LeviM.Advanced glycation end products: A nephrologist's perspective.Am J Kidney Dis2000; 35: 365–80.
2.
MiyataT., van Ypersele de StrihouC., KurokawaK., BaynesJ.W.Alterations in nonenzymatic biochemistry in uremia: Origin and significance of “carbonyl stress” in long-term uremic complications.Kidney Int1999; 55: 389–99.
3.
InagiR., MiyataT.Oxidative protein damage with carbohydrates and lipids in uremia: “carbonyl stress.”Blood Purif1999; 17: 95–8.
4.
SchalkwijkC.G., PosthumaN., ten BrinkH.J., ter WeeP.M., TeerlinkT.Induction of 1,2-dicarbonyl compounds, intermediates in the formation of advanced glycation endproducts, during heat-sterilization of glucose-based peritoneal dialysis fluids.Perit Dial Int1999; 19: 325–33.
5.
ZeierM., SchwengerV., DeppischR., HaugU., WeigelK., BahnerU.Glucose degradation products in PD fluids: Do they disappear from the peritoneal cavity and enter the systemic circulation?Kidney Int2003; 63: 298–305.
6.
AhmedM.U., Brinkmann FryeE., DegenhardtT.P., ThorpeS.R., BaynesJ.W.N-epsilon-(carboxyethyl)lysine, a product of the chemical modification of proteins by methylglyoxal, increases with age in human lens proteins.Biochem J1997; 324: 565–70.
7.
JanuszewskiA.S., AldersonN.L., MetzT.O., ThorpeS.R., BaynesJ.W.Role of lipids in chemical modification of proteins and development of complications in diabetes.Biochem Soc Trans2003; 31: 1413–16.
8.
MiyataT., HorieK., UedaY., FujitaY., IzuharaY., HiranoH.Advanced glycation and lipidoxidation of the peritoneal membrane: Respective roles of serum and peritoneal fluid reactive carbonyl compounds.Kidney Int2000; 58: 425–35.
9.
SakataN., ImanagaY., MengJ., TachikawaY., TakebayashiS., NagaiR.Increased advanced glycation end products in atherosclerotic lesions of patients with end-stage renal disease.Atherosclerosis1999; 142: 67–77.
10.
YokotaS., KumanoK., HyodoT., SakaiT., IzumiG., HashimotoA.In vitro and in vivo generation and kinetics of glycosylation products in peritoneal dialysis effluents.Adv Perit Dial1998; 14: 195–9.
11.
InagiR., MiyataT., YamamotoT., SuzukiD., UrakamiK., SaitoA.Glucose degradation product methylglyoxal enhances the production of vascular endothelial growth factor in peritoneal cells: Role in the functional and morphological alterations of peritoneal membranes in peritoneal dialysis.FEBS Lett1999; 463: 260–4.
12.
RuizM.C., Portero-OtinM., PamplonaR., RequenaJ.R., PratJ., LafargaM.A.Chemical and immunological characterization of oxidative nonenzymatic protein modifications in dialysis fluids.Perit Dial Int2003; 23: 23–32.
13.
SakataN., ImanagaY., MengJ., TachikawaY., TakebayashiS., NagaiR.Increased advanced glycation end products in atherosclerotic lesions of patients with end-stage renal disease.Atherosclerosis1999; 142: 67–77.
14.
BoulangerE., WautierM.P., WautierJ.L., BovalB., PanisY., WernertN.AGEs bind to mesothelial cells via RAGE and stimulate VCAM-1 expression.Kidney Int2002; 61: 148–56.
15.
KislingerT., FuC., HuberB., QuW., TaguchiA., Du YanS.N(epsilon)-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression.J Biol Chem1999; 274: 31740–9.
16.
KoningsC.J., KoomanJ.P., SchonckM., GladziwaU., WirtzJ., van den Wall BakeA.W.Effect of icodextrin on volume status, blood pressure and echocardiographic parameters: A randomized study.Kidney Int2003; 63: 1556–63.
17.
DaviesS.J., WoodrowG., DonovanK., PlumJ., WilliamsP., JohanssonA.C.Icodextrin improves the fluid status of peritoneal dialysis patients: Results of a double-blind randomized controlled trial.J Am Soc Nephrol2003; 14: 2338–44.
18.
SchalkwijkC.G., ter WeeP.M., TeerlinkT.Reduced 1,2-dicarbonyl compounds in bicarbonate/lactate-buffered peritoneal dialysis (PD) fluids and PD fluids based on glucose polymers or amino acids.Perit Dial Int2000; 20: 796–8.
19.
PosthumaN., ter WeeP.M., NiessenH., DonkerA.J., VerbrughH.A., SchalkwijkC.G.Amadori albumin and advanced glycation end-product formation in peritoneal dialysis using icodextrin.Perit Dial Int2001; 21: 43–51.
20.
UedaY., MiyataT., GoffinE., YoshinoA., InagiR., IshibashiY.Effect of dwell time on carbonyl stress using icodextrin and amino acid peritoneal dialysis fluids.Kidney Int2000; 58: 2518–24.
21.
TeerlinkT., BartoR., ten BrinkH.J., SchalkwijkC.G.Measurement of N{epsilon}-(carboxymethyl)lysine and N{epsilon}-(carboxyethyl)lysine in human plasma protein by stable-isotope-dilution tandem mass spectrometry.Clin Chem2004; 50: 1222–8.
22.
KoningsC.J., KoomanJ.P., van der SandeF.M., LeunissenK.M.Fluid status in peritoneal dialysis: What's new?Perit Dial Int2003; 23: 284–90.
23.
van de KerkhofJ., SchalkwijkC.G., KoningsC.J., CheriexE.C., van der SandeF.M., ter WeeP.M.N∊-(carboxymethyl)lysine, N∊-(carboxyethyl)lysine and vascular cell adhesion molecule-1 (VCAM-1) in relation to peritoneal glucose prescription and residual renal function; a study in peritoneal dialysis patients.Nephrol Dial Transplant2004; 19: 910–16.
24.
GotloibL., WajsbrotV., ShostakA.Mesothelial dysplastic changes and lipid peroxidation induced by 7.5% icodextrin.Nephron2002; 92: 142–55.
HenleT., DeppischR., BeckW., HergesellO., HanschG.M., RitzE.Advanced glycated end-products (AGE) during haemodialysis treatment: Discrepant results with different methodologies reflecting the heterogeneity of AGE compounds.Nephrol Dial Transplant1999; 14: 1968–75.
27.
SchwedlerS.B., MetzgerT., SchinzelR., WannerC.Advanced glycation end products and mortality in hemodialysis patients.Kidney Int2002; 62: 301–10.
